MedTrace Logo

A Study of PHN-012 in Patients With Advanced Solid Tumors

NCT07127874 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 165

Last updated 2026-04-17

No results posted yet for this study

Summary

This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.

Conditions

Interventions

DRUG

PHN-012

PHN-012 is an ADC

Sponsors & Collaborators

  • Pheon Therapeutics

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-23
Primary Completion
2027-09-30
Completion
2028-05-31
FDA Drug
Yes

Countries

  • United States
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07127874 on ClinicalTrials.gov